Literature DB >> 103331

The disposition and metabolism of flurbiprofen in several species including man.

P C Risdall, S S Adams, E L Crampton, B Marchant.   

Abstract

Flurbiprofen was rapidly absorbed in all species studied. 2. Half-lives of elimination measured 0 to 12 h after a single dose were: mouse 3.4 h, rat 2.5 h, dog 10.1 h, baboon 3.1 h and man 3.9 h. A second phase of elimination was seen in the dog. Flurbiprofen accumulated in the circulation of the dog on repeated dosing. 3. After dosing with [14C]flurbiprofen, tissue levels of radioactivity in dog and baboon were similar to that in plasma. In the rat, levels were slightly elevated in liver, kidney, large intestine and thyroid after repeated dosing. 4. The dog excreted equal amounts of radioactivity in urine and faeces. In other species renal excretion was the more important route. 5. Six metabolites have been detected, the most important being: 2-(2-fluoro-4'-hydroxy-4-biphenylyl)propionic acid (metabolite 1), 2-(i-fluoro-3',4'-dihydroxy-4-biphenylyl)propionic acid (metabolite 2) and 2-(2-fluoro-3'-hydroxy-4'-methoxy-4-biphenylyl)propionic acid (metabolite 3). The proportions of the metabolites and the extents of their conjugation varied among the species. 6. Metabolites were detected in the circulation of rat, mouse and baboon but not in dog and man. 7. Flurbiprofen did not affect the hepatic drug-metabolizing enzyme system of rat. 8. Flurbiprofen was extensively bound to serum protein of rat, dog, baboon and man.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 103331     DOI: 10.3109/00498257809069581

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  21 in total

1.  Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines.

Authors:  L Igarza; A Soraci; N Auza; H Zeballos
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

2.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

3.  Stereoselective disposition of flurbiprofen in normal volunteers.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

4.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

5.  Metabolism of 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole (SM-8849) in rats.

Authors:  M Yabuki; J Shimakura; M Ito; H Kanamaru; K Iba; I Nakatsuka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.441

6.  Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.

Authors:  Oscar Sasso; Marco Migliore; Damien Habrant; Andrea Armirotti; Clara Albani; Maria Summa; Guillermo Moreno-Sanz; Rita Scarpelli; Daniele Piomelli
Journal:  FASEB J       Date:  2015-03-10       Impact factor: 5.191

Review 7.  Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.

Authors:  J A Vale; T J Meredith
Journal:  Med Toxicol       Date:  1986 Jan-Feb

8.  Relationship between the ocular and systemic disposition of flurbiprofen: the effect of altered protein dynamics at steady state.

Authors:  D D Tang-Liu; S Liu
Journal:  J Pharmacokinet Biopharm       Date:  1987-08

Review 9.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 10.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.